The size of the Acute Ischemic Stroke Treatment & Diagnosis Market in LATAM was valued at USD 306.24 million in 2022 and estimated to be growing at a CAGR of 6.9%, to reach USD 427.51 million by 2027.
The increased occurrence of acute ischemic stroke is propelling the Latin American acute ischemic stroke treatment and diagnostics market, including diagnostic and surgical treatments. Because of emboli, thrombus, or atherosclerosis in the cerebral arteries, blood flow to the brain is cut off in an acute ischemic stroke. According to the World Health Organization, heart illness claims the lives of about 18 million people every year (WHO). Heart attacks and mild strokes are the two most common causes of death worldwide.
According to the Centers for Disease Control and Prevention, ischemic strokes account for 87% of all strokes. According to the Prevention Program, stroke is one of the primary causes of long-term impairment, particularly in the elderly. Stroke is also responsible for one out of every twenty deaths. Factors that boost the further expansion of the market include rising tobacco consumption and diabetes among the growing population. The National Institutes of Health has announced financing for the Stroke Preclinical Assessment Network (SPAN), which will ensure that innovative individual treatments for acute ischemic stroke are assessed in rats systematically and successfully. The National Institutes ask researchers of Health to make key preclinical study criteria and techniques identical to those used in clinical trials. Because many medications fail to pass individual human tests, the goal is to enhance clinical trial results.
One of the primary drivers of the market is the expanding geriatric population, which is more sensitive to stroke than younger populations in both developed and developing countries.
Long-term testing of medications after the beginning of the stroke and clinical trials, including a poor selection of patients for investigation, are key challenges in expanding the Latin American acute ischemic stroke therapy and diagnosis market. Overuse drugs and the high expense of surgery are likely to hamper Latin America's growth. The expansion of the market is expected to be hindered by a lack of sufficient understanding in various emerging countries across the continent. The rapid emergence of a novel coronavirus (COVID-19) has been a significant source of concern for the medical community. The COVID-19 has had a deleterious effect on the rate of ischemic stroke.
This research report on the Latin America acute ischemic stroke treatment & diagnosis market has been segmented and sub-segmented into the following categories:
By Diagnostic Type:
By Surgery Type:
Acute Ischemic Stroke Treatment and Diagnosis in Latin America is predicted to account for a substantial share in the global market during the forecast period. Advancements in surgical procedures and the rising prevalence of acute ischemic stroke are driving the market. Other essential drivers driving market expansion include an aging population, increased awareness of less invasive surgical methods, and rising healthcare spending. A huge patient base and a growing population with an enormous risk of suffering strokes in the future are further anticipated to encourage the growth rate of the market. In addition, increased fatality rates linked to strokes highlight the urgent need for new medications and diagnostic technology.
Brazil was the largest market in the Latin American region in 2020. As the number of surgical operations used to treat strokes develops in tandem with the number of cases of cerebral ischemia, the market is growing. In addition, rising healthcare spending, new surgical technology, and an increasing need for minimally continuous operations drive the demand for acute ischemic stroke detection and treatment in Latin America.
Mexico, following Brazil, is predicted to accelerate at a healthy rate in the Latin American market during the forecast period. Technological developments in surgery, aging, the increased need for minimally invasive surgery, and rising medical expenditures are other important drivers of the acute ischemic stroke diagnostic and treatment market growth.
KEY MARKET PLAYERS:
Companies like Abbott Laboratories, Covidien plc, Philips Healthcare, Johnson & Johnson, Penumbra, Inc., GE Healthcare, Siemens Healthcare, Stryker Corporation (Concentric Medical, Inc.), and Hitachi, Ltd are playing a leading role in the LATAM Acute Ischemic Stroke Treatment & Diagnosis Market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com